IRWD
NASDAQ · Biotechnology
Ironwood Pharmaceuticals Inc
$3.54
+0.02 (+0.57%)
Financial Highlights (FY 2026)
Revenue
299.12M
Net Income
24.26M
Gross Margin
100.0%
Profit Margin
8.1%
Rev Growth
-10.3%
D/E Ratio
0.61
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 30.9% | 30.9% |
| Operating Margin | 33.3% | 29.9% | 21.9% | 20.5% |
| Profit Margin | 8.1% | 7.7% | 17.0% | 18.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 299.12M | 333.54M | 73.58M | 81.79M |
| Gross Profit | 299.12M | 333.54M | 22.74M | 25.28M |
| Operating Income | 99.49M | 99.84M | 16.11M | 16.74M |
| Net Income | 24.26M | 24.35M | 12.49M | 15.09M |
| Gross Margin | 100.0% | 100.0% | 30.9% | 30.9% |
| Operating Margin | 33.3% | 29.9% | 21.9% | 20.5% |
| Profit Margin | 8.1% | 7.7% | 17.0% | 18.5% |
| Rev Growth | -10.3% | -10.3% | +11.9% | +19.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 110.10M | 110.10M | 202.65M | 191.91M |
| Total Equity | 181.27M | 181.27M | 432.39M | 478.38M |
| D/E Ratio | 0.61 | 0.61 | 0.47 | 0.40 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 101.39M | 107.40M | 23.02M | 27.07M |
| Free Cash Flow | — | — | 13.98M | 17.94M |